Medix Biochemica Welcomes Aydin Parast as Chief Commercial Officer, North America & Europe

We are pleased to announce that Aydin Parast will be joining Medix Biochemica in late July 2025 as our new Chief Commercial Officer for North America and Europe. Aydin brings nearly two decades of experience in the in vitro diagnostics (IVD) industry, most recently serving at LGC, where he led corporate accounts & strategy within the diagnostics and genomics unit. His leadership has been instrumental in driving strategic partnerships and commercial growth across global markets.

A Message from Aydin

“Hi Medix Biochemica Team,
I am so proud and excited to be joining this amazing company and team. Having worked in the IVD industry for nearly 20 years, I share the same passion and purpose as you all: making a positive impact on patient outcomes. Having followed Medix Biochemica over the past decade, I’ve witnessed your fantastic growth and success. I cannot wait to get to know you all better and am really looking forward to working with you closely as one team, continuing to drive the business and company to the next phase.  Finally, I couldn’t send this note without mentioning how much I love “#WeIVDoThat” - it’s simply genius! Thank you again for this opportunity and see you all in July!” 

Strengthening Our Global Commercial Strategy

Aydin’s appointment comes at a time of continued growth and transformation for Medix Biochemica. As we expand our global reach, we are evolving our commercial strategy to better align with customer needs and market dynamics. With his deep industry expertise and strategic mindset, Aydin will play a key role in advancing our commercial operations across North America and Europe - two of our most important and dynamic regions.

Aydin Brings Global Experience in Diagnostics

Aydin Parast brings nearly 20 years of international experience in the diagnostics industry. He has held senior roles across both public and private sectors, including:

• Leading corporate strategy and key account development at LGC Diagnostics, where he played a pivotal role in several high-profile acquisitions such as SeraCare Life Sciences, Technopath, and The Native Antigen Company.
• Contributing to public health diagnostics during his time with the UK’s National Health Service (NHS).
• Gaining operational and commercial expertise at Roche Diagnostics.
  

Looking Ahead

Aydin joins Medix Biochemica during a milestone year - our 40th anniversary - as we reflect on our legacy and look ahead to the future. His appointment underscores our commitment to strengthening our global presence and delivering even greater value to our customers and partners.

Please join us in giving Aydin a warm welcome to the Medix Biochemica family!